Furthermore, compared with the control group, hepatic steatosis (fatty liver group) led to decreased mRNA abundance of RXRα, ACO, CPT1, CPT2, LCAD, Nrf1 and TFAM (p < 0.05 or p < 0.01). The gene discussed is ACADL; the disease is fatty liver disease.